Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,699.38
(
1.01%
)
US TECH 100
23,937.60
(
-0.32%
)
Dow Jones
46,946.41
(
0.83%
)
Brent Oil
100.65
(
2.39%
)
Bitcoin
73,751.25
(
-1.46%
)
News Focus
News Focus
Post# of 257250
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122790
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 78581

Wednesday, 01/05/2011 7:27:02 AM

Wednesday, January 05, 2011 7:27:02 AM

Post# of 257250
Bayer/JNJ announce multiple Xarelto regulatory submissions:

http://www.bayer.com/en/news-detail.aspx?newsid=14326

• Initial EU submission for stroke prevention in AF, based on ROCKET-AF study (#msg-56712414,

• Initial EU submission for treatment of acute DVT, based on EINSTEIN-DVT study (#msg-53887547).

• FDA re-submission for VTE prevention following hip/knee surgery in response to FDA CRL issued in May 2009 (#msg-38200098).

Note: Xarelto was approved in the EU in 2008 for VTE prevention following hip/knee surgery (#msg-30972846), the indication for which JNJ is seeking FDA approval.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Where Real Traders Talk Markets

Join thousands of traders sharing insights, catalysts, and charts.

Join Today